DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,798 filers reported holding DANAHER CORPORATION in Q2 2021. The put-call ratio across all filers is 1.06 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $373,000 | -43.1% | 1,273 | -36.1% | 0.16% | -45.5% |
| Q4 2021 | $656,000 | +8.1% | 1,993 | 0.0% | 0.30% | -2.9% |
| Q3 2021 | $607,000 | +9.8% | 1,993 | -3.3% | 0.31% | +10.0% |
| Q2 2021 | $553,000 | +17.9% | 2,061 | -1.2% | 0.28% | +2.9% |
| Q1 2021 | $469,000 | -13.0% | 2,085 | -14.0% | 0.27% | -15.8% |
| Q4 2020 | $539,000 | -5.6% | 2,425 | -8.5% | 0.32% | -21.8% |
| Q3 2020 | $571,000 | -56.7% | 2,650 | -64.5% | 0.41% | -59.5% |
| Q2 2020 | $1,319,000 | +32.6% | 7,457 | +3.7% | 1.02% | +12.3% |
| Q1 2020 | $995,000 | -39.3% | 7,192 | -32.7% | 0.91% | -25.4% |
| Q4 2019 | $1,640,000 | +0.1% | 10,685 | -5.8% | 1.22% | -13.0% |
| Q3 2019 | $1,639,000 | -15.4% | 11,348 | -16.3% | 1.40% | -28.2% |
| Q2 2019 | $1,937,000 | +4.8% | 13,550 | -3.2% | 1.95% | +1.5% |
| Q1 2019 | $1,848,000 | +28.0% | 13,995 | -0.0% | 1.92% | +10.3% |
| Q4 2018 | $1,444,000 | – | 13,999 | – | 1.74% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |